Nexalin Technology

Nexalin Technology Stock-Based Compensation

The Stock-Based Compensation (SBC) of Nexalin Technology (NXL) as of Oct 22, 2026 is 3.12 M USD. In the previous year, Stock-Based Compensation (SBC) was 3.56 M USD — a change of -12.28% (lower).

Stock-Based Compensation

3.12 MUSD

YoY

-12.28%

Last updated:

Stock-Based Compensation (SBC) of Nexalin Technology is 2025 3.12 M USD. Stock-Based Compensation (SBC) of Nexalin Technology was 2024 3.56 M USD. It decreases by -12.28% lower compared to the previous year.

The Nexalin Technology Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
562,735.00 USD
Jan 1, 2020
1.96 M USD
Jan 1, 2021
4.48 M USD
Jan 1, 2022
270,670.00 USD
Jan 1, 2023
2.41 M USD
Jan 1, 2024
3.56 M USD
Jan 1, 2025
3.12 M USD
The Nexalin Technology Stock-Based Compensation history
YEARStock-Based CompensationYoY
3.12 MUSD-12.28%
3.56 MUSD+47.53%
2.41 MUSD+791.63%
270,670.00USD-93.96%
4.48 MUSD+128.53%
1.96 MUSD+248.21%
562,735.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Stock-Based Compensation (SBC) of Nexalin Technology is 3.12 M USD in 2025.

Stock-Based Compensation (SBC) of Nexalin Technology changed from 3.56 M USD to 3.12 M USD, representing a -12.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nexalin Technology

All Key Metrics — Nexalin Technology